Literature DB >> 7895928

Effect of intravenous infusion of omeprazole and ranitidine on twenty-four-hour intragastric pH in patients with a history of duodenal ulcer.

S Kiilerich1, T Rannem, L Elsborg.   

Abstract

The effect on intragastric pH of two different dose regimens of continuous intravenous infusion of omeprazole (4 or 8 mg/h after a bolus of 80 mg), and ranitidine (0.25 mg/kg/h after a bolus of 50 mg) was studied in 10 patients with duodenal ulcer disease in symptomatic remission. The pH was monitored over 24-hour periods during fasting in a cross-over, randomised design including a baseline period. With the high omeprazole dose it was possible to maintain a pH > or = 4 in all patients but 1 and 6 of the patients also maintained a pH > or = 6. The lower dose of omeprazole seemed to be somewhat less effective. Continuous infusion of ranitidine was as efficient as the higher omeprazole infusion although with a tendency to decreased pH levels towards the end of the 24-hour period. Thus, in order to obtain consistently high pH levels of 4-6 over a prolonged period a continuous infusion of omeprazole, an 80-mg bolus plus a continuous infusion of 8 mg/h seem to be needed.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7895928     DOI: 10.1159/000201217

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  7 in total

Review 1.  Appropriate use of intravenous proton pump inhibitors in the management of bleeding peptic ulcer.

Authors:  Venodhar R Julapalli; David Y Graham
Journal:  Dig Dis Sci       Date:  2005-07       Impact factor: 3.199

2.  Intravenous proton pump inhibitors for peptic ulcer bleeding: Clinical benefits and limits.

Authors:  Hsiu-Chi Cheng; Bor-Shyang Sheu
Journal:  World J Gastrointest Endosc       Date:  2011-03-16

3.  Efficacy of primed infusions with high dose ranitidine and omeprazole to maintain high intragastric pH in patients with peptic ulcer bleeding: a prospective randomised controlled study.

Authors:  J Labenz; U Peitz; C Leusing; B Tillenburg; A L Blum; G Börsch
Journal:  Gut       Date:  1997-01       Impact factor: 23.059

4.  Pharmacokinetics of omeprazole given by continuous intravenous infusion to patients with varying degrees of hepatic dysfunction.

Authors:  Josep M Piqué; Faust Feu; Gloria de Prada; Kerstin Röhss; Göran Hasselgren
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

5.  Intravenous non-high-dose pantoprazole is equally effective as high-dose pantoprazole in preventing rebleeding among low risk patients with a bleeding peptic ulcer after initial endoscopic hemostasis.

Authors:  Chih-Ming Liang; Jyong-Hong Lee; Yuan-Hung Kuo; Keng-Liang Wu; Yi-Chun Chiu; Yeh-Pin Chou; Ming-Luen Hu; Wei-Chen Tai; King-Wah Chiu; Tsung-Hui Hu; Seng-Kee Chuah
Journal:  BMC Gastroenterol       Date:  2012-03-28       Impact factor: 3.067

6.  Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study.

Authors:  Chih-Ming Liang; Chien-Ning Hsu; Wei-Chen Tai; Shih-Cheng Yang; Cheng-Kun Wu; Chih-Wei Shih; Ming-Kun Ku; Lan-Ting Yuan; Jiunn-Wei Wang; Kuo-Lun Tseng; Wei-Chih Sun; Tsung-Hsing Hung; Seng-Howe Nguang; Pin-I Hsu; Deng-Chyang Wu; Seng-Kee Chuah
Journal:  Medicine (Baltimore)       Date:  2016-09       Impact factor: 1.889

7.  Risk factors of poor prognosis and impairment of activities of daily living in patients with hemorrhagic gastroduodenal ulcers.

Authors:  Junya Arai; Jun Kato; Nobuo Toda; Ken Kurokawa; Chikako Shibata; Shigeyuki Kurosaki; Kazuyoshi Funato; Mayuko Kondo; Kaoru Takagi; Kentaro Kojima; Takamasa Ohki; Michiharu Seki; Kazumi Tagawa
Journal:  BMC Gastroenterol       Date:  2021-01-06       Impact factor: 3.067

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.